AZN vs MMSI

AstraZeneca's deterministic health score is concerning with a Piotroski F-Score of 4/9, indicating marginal financial stability. While profitability metrics like ROE (21.67%) and gross margin (83.26%) are strong, the current price of $92.95 trades significantly above the Graham Number of $45.06, reflecting high growth expectations. Revenue and earnings growth are robust (12% and 78% YoY, respectively), but recent earnings surprises have been volatile, including a -25.9% miss in Q3 2025. Analysts maintain a strong_buy recommendation, though insider selling and weak technical trends (10/100) suggest caution near-term.

MMSI presents a dichotomy between strong fundamental growth and poor market sentiment. While the Piotroski F-Score of 4/9 indicates stable but not strong financial health, the company boasts an exceptional track record of earnings beats over 25 quarters and strong YoY earnings growth of 38.8%. However, the stock is currently trading at $70.54, which is a premium to its Intrinsic Value ($62.83) and significantly above its Graham Number ($35.75). Bearish insider activity and a 0/100 technical trend offset the bullish analyst target of $101.18.